Growth via acquisitions Fulgent has actively expanded through strategic acquisitions (StrataDx, Bako Diagnostics) in 2025, signaling a channel for upsell of integrated genomics services, pathology workflows, and enhanced laboratory capacity to enterprise clients.

Platform-driven offerings A broad, self-described foundational technology platform underpins diverse testing lines—from oncology and infectious diseases to reproductive health—creating cross-sell opportunities to existing CLIA/CAP customers seeking comprehensive genomic solutions.

Partnership potential Recent and ongoing partnerships with major players (Foundation Medicine, Mission Bio collaboration) indicate receptivity to co-developed tests and shared data insights, making collaboration with Fulgent a viable option for joint development and distribution.

Revenue stabilization signals First-quarter 2026 revenue declined modestly year over year, suggesting potential to position premium, high-value testing panels and managed service offerings to stabilize growth and reduce customer churn among oncology and rare disease segments.

Global tech enablement Utilization of a robust tech stack (AWS, Azure DevOps, Epic Beaker, TypeScript) and cloud-based platforms supports scalable service delivery; this enables selling to large clinics and health systems seeking reliable, interoperable genomic testing integrations.